-$0.63 Earnings Per Share Expected for Crispr Therapeutics AG (CRSP) This Quarter
Brokerages expect Crispr Therapeutics AG (NASDAQ:CRSP) to post earnings per share of ($0.63) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Crispr Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.51) and the lowest estimate coming in at ($0.84). Crispr Therapeutics reported earnings of ($0.62) per share during the same quarter last year, which suggests a negative year over year growth rate of 1.6%. The firm is expected to announce its next earnings results on Wednesday, November 14th.
According to Zacks, analysts expect that Crispr Therapeutics will report full-year earnings of ($2.89) per share for the current year, with EPS estimates ranging from ($3.16) to ($2.38). For the next fiscal year, analysts anticipate that the company will report earnings of ($3.09) per share, with EPS estimates ranging from ($3.70) to ($1.90). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that cover Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Wednesday, August 8th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.19). Crispr Therapeutics had a negative net margin of 189.60% and a negative return on equity of 35.18%. The business had revenue of $1.09 million during the quarter, compared to analyst estimates of $1.47 million.
CRSP stock opened at $47.95 on Tuesday. Crispr Therapeutics has a 1 year low of $16.16 and a 1 year high of $73.90.
In other Crispr Therapeutics news, Director Kurt Von Emster sold 650,000 shares of the business’s stock in a transaction on Monday, May 14th. The shares were sold at an average price of $54.39, for a total transaction of $35,353,500.00. Following the completion of the transaction, the director now owns 5,629 shares of the company’s stock, valued at approximately $306,161.31. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction on Thursday, July 5th. The stock was sold at an average price of $62.00, for a total transaction of $465,000.00. Following the transaction, the director now directly owns 5,816 shares of the company’s stock, valued at approximately $360,592. The disclosure for this sale can be found here. In the last ninety days, insiders sold 754,236 shares of company stock valued at $41,731,001. 37.70% of the stock is owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the business. Rockefeller Capital Management L.P. acquired a new position in Crispr Therapeutics during the 2nd quarter worth $116,000. First Mercantile Trust Co. acquired a new position in Crispr Therapeutics during the 2nd quarter worth $141,000. SeaCrest Wealth Management LLC lifted its position in Crispr Therapeutics by 202.9% during the 2nd quarter. SeaCrest Wealth Management LLC now owns 2,726 shares of the company’s stock worth $160,000 after acquiring an additional 1,826 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Crispr Therapeutics by 66.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,827 shares of the company’s stock worth $166,000 after acquiring an additional 1,127 shares during the last quarter. Finally, Private Advisor Group LLC acquired a new position in Crispr Therapeutics during the 2nd quarter worth $227,000. 37.65% of the stock is owned by hedge funds and other institutional investors.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Recommended Story: Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.